$0.547500
0.035.44%
At close: Jul 17, 7:56 AM EDT
$0.577300
0.035.44%
After Hours: Jul 17, 7:56 AM EDT
15 minutes delayed
Comments
Loading...
Viracta Therapeutics
VIRXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Viracta Therapeutics (NASDAQ:VIRX) Stock, Analyst Ratings, Price Targets, Forecasts
Viracta Therapeutics Inc has a consensus price target of $7.2 based on the ratings of 5 analysts. The high is $11 issued by Oppenheimer on May 23, 2024. The low is $4 issued by HC Wainwright & Co. on April 16, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, Oppenheimer, and HC Wainwright & Co. on May 23, 2024, April 17, 2024, and April 16, 2024, respectively. With an average price target of $9.33 between Oppenheimer, Oppenheimer, and HC Wainwright & Co., there's an implied 1516.72% upside for Viracta Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
RBC Capital
SVB Securities
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Viracta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/23/2024 | Buy Now | 1805.42% | Oppenheimer | Hartaj Singh | $13 → $11 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 2151.86% | Oppenheimer | Hartaj Singh | → $13 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | 592.88% | HC Wainwright & Co. | Robert Burns | → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 592.88% | HC Wainwright & Co. | Robert Burns | → $4 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 592.88% | HC Wainwright & Co. | Robert Burns | $10 → $4 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 939.32% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
| 10/05/2023 | Buy Now | 1112.54% | RBC Capital | Gregory Renza | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | Buy Now | 1112.54% | RBC Capital | Gregory Renza | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | Buy Now | 766.1% | SVB Securities | Andrew Berens | $10 → $5 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 1632.2% | HC Wainwright & Co. | Robert Burns | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 1632.2% | EF Hutton | Tony Butler | → $10 | Initiates | → Buy | Get Alert |
| 07/05/2023 | Buy Now | 1632.2% | HC Wainwright & Co. | Robert Burns | $33 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 5616.27% | HC Wainwright & Co. | Robert Burns | $35 → $33 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 1112.54% | RBC Capital | Gregory Renza | $8 → $7 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 1805.42% | SVB Securities | Andrew Berens | $11 → $11 | Maintains | Outperform | Get Alert |
| 03/27/2023 | Buy Now | 2671.52% | Oppenheimer | Hartaj Singh | $14 → $16 | Maintains | Outperform | Get Alert |
| 03/14/2023 | Buy Now | 1285.76% | RBC Capital | Gregory Renza | → $8 | Reiterates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 5962.71% | HC Wainwright & Co. | Robert Burns | → $35 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 1285.76% | RBC Capital | Gregory Renza | $10 → $8 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 1805.42% | SVB Securities | Andrew Berens | → $11 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Viracta Therapeutics (VIRX) stock?
The latest price target for Viracta Therapeutics (NASDAQ:VIRX) was reported by Oppenheimer on May 23, 2024. The analyst firm set a price target for $11.00 expecting VIRX to rise to within 12 months (a possible 1805.42% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
The latest analyst rating for Viracta Therapeutics (NASDAQ:VIRX) was provided by Oppenheimer, and Viracta Therapeutics maintained their outperform rating.
When was the last upgrade for Viracta Therapeutics (VIRX)?
There is no last upgrade for Viracta Therapeutics
When was the last downgrade for Viracta Therapeutics (VIRX)?
There is no last downgrade for Viracta Therapeutics.
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on May 23, 2024 so you should expect the next rating to be made available sometime around May 23, 2025.
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $13.00 to $11.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.58, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.